
Dr. Stella Lee explores the past, present and future implementation of guidelines into daily practice
In this ADVENT symposium at the 2024 EADV meeting, Professor Dedee Murrell reviews the current treatment guidelines for bullous pemphigoid (BP) and the emergence of targeted therapies including a highlight of the LIBERTY-BP ADEPT interim results.
Dr Gutiérrez Junquera discusses ESPGHAN guidelines, clinical data, and long-term management strategies for pediatric EoE.
Learn from Drs. Dellon and Wechsler as they discuss best practices in EoE, including highlights from EoE guidelines in the US and EU.

Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.
Join experts Dédée Murrell, Donna Aline Culton, Joost Meijer and Enno Schmidt for an educational presentation on the clinical presentation, disease burden, diagnosis, and underlying pathophysiology of bullous pemphigoid (BP). Dive deeper into unmet needs and treatment challenges faced by these patients and how targeted therapies may address them.
In this podcast, Dr. Teri Greiling and Dr. Daniel Butler discuss the enormous burden patients with bullous pemphigoid experience and how our understanding of the disease pathophysiology may help address unmet treatment needs.
Meet Fernando. Journey through his clinical profile, applying guideline-based checklists to reach a consensus regarding his diagnosis.
Unpack the keys to successful disease control in CRSwNP alongside expert Prof. Vibeke Backer. Learn how to navigate treatment pathways for improved patient quality of life.
Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.

Drs. Dellon and Dickstein host a Symposium where audience members solve puzzles to uncover cutting-edge knowledge of eosinophilic esophagitis (EoE). This event is neither sponsored by nor endorsed by ACG.

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.